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Abstract
Background: Limited real-world data are currently available on hypoglycemia in diabetes patients. The International
Operations Hypoglycemia Assessment Tool (IO HAT) study was designed to estimate hypoglycemia in insulin-treated type
I (T1DM) and type II (T2DM) diabetes mellitus patients from 9 countries. The data from Turkey cohort are presented here.
Methods: A non-interventional study to determine the hypoglycemia incidence, retrospectively and prospectively, in
Turkish T1DM and T2DM patients using a 2-part self-assessment questionnaire.
Results: Overall, 2348 patients were enrolled in the Turkey cohort (T1DM= 306 patients, T2DM= 2042 patients). In T1DM
patients, 96.8% patients reported hypoglycemic events (Incidence rate [IR]: 68.6 events per patient-year [ppy]),
prospectively, while 74.0% patients reported hypoglycemic events (IR: 51.7 events ppy), retrospectively. In T2DM
patients, 95.9% patients (IR: 28.3 events ppy) reported hypoglycemic events, prospectively, while 53.6% patients
(IR: 23.0 events ppy) reported hypoglycemic events, retrospectively. Nearly all patients reported hypoglycemia
during the prospective period.
Conclusions: This is a first patient-reported dataset on hypoglycemia in Turkish, insulin-treated diabetes patients. A
high incidence of patient-reported hypoglycemia confirms that hypoglycemia remains under-estimated. Hypoglycemia
increased healthcare utilization impacting patients’ quality of life. Hypoglycemia remains a common side effect with
insulin-treatment and strategies to optimize therapy and reduce hypoglycemia occurrence in diabetes patients are
required.
Trial registration: Clinicaltrials.gov, NCT02306681 (Date of registration: 12 Nov 2014; retrospectively registered).
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Background
Insulin therapy remains integral to treatment of type I
diabetes mellitus (T1DM) and long-term type II diabetes
mellitus (T2DM) [1]. A good glycemic control is essen-
tial to minimize development of microvascular compli-
cations and macrovascular events [2]. Hypoglycemia is
the main hurdle for achieving optimal glycemic control
in patients on insulin therapy [3]. Development of strat-
egies or therapies to control hypoglycemia is important
to help individuals achieve glycemic targets [4]. Achiev-
ing optimum glycemic control following the diagnosis of
T2DM is vital to improving clinical outcomes, yet many
patients and clinicians are hesitant to initiate and inten-
sify insulin therapy. Reasons for this are manifold
including lack of time, clinical expertise and patient un-
derstanding. However, considerable progress can be
achieved with patient education and awareness programs
soon after diagnosis [5].
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Despite the apparent high risk of hypoglycemia, only a
few studies have been conducted to evaluate the incidence
rate of hypoglycemia in a real-world setting.
Hypoglycemia is commonly reported in a clinical trial
context; however, these studies seldom reflect real-life
clinical practice due to rigorous inclusion and exclusion
criteria involved, and continuous treatment and follow-up.
Increasing evidence on growing incidence of diabetes in
low- and middle-income countries has been reported [6].
According to two population-based studies, the prevalence
of T2DM in Turkey increased from 7.2% to 16.5% within
12 years [7, 8]. Current knowledge on hypoglycemia comes
from a few studies in North American or European popu-
lations and very limited data are available on hypoglycemia
in Turkish diabetes patients [9, 10].
This paper describes the results from the Turkey cohort
of the International Operations Hypoglycemia Assessment
Tool (IO HAT) study which was conducted in 9 countries.
The IO HAT study builds on findings from the global
HAT study that was conducted in 24 countries [11]. The
IO HAT study is an observational study aimed at enhan-
cing the clinical understanding of hypoglycemia, and its
clinical, social and economic consequences. In turn, this
will help to identify cost-effective solutions to improve
blood glucose control and Quality of Life (QOL) for
patients with diabetes. The current study aims to assess
hypoglycemia retrospectively and prospectively among in-
sulin treated patients with T1DM or T2DM.
Methods
Study design
The Turkey cohort of the IO HAT study was a non-
interventional, multi-center, 6-month and 4-week
retrospective and 4-week prospective study to assess
hypoglycemia in insulin-treated diabetes patients.
The study was carried out at 92 sites in Turkey. The
study design is described in Fig. 1. The study protocol
and assessments were conducted in accordance with the
Declaration of Helsinki (2013) and the Guidelines for
Good Pharmacoepidemiology Practices (2007), and
approved by an Ethics Committee. All study materials
were translated into Turkish, and data obtained were
translated back into English for analysis.
Study population
The study was conducted in male or female T1DM or
T2DM patients treated with insulin for more than
12 months and who were 18 years or older, ambulatory,
literate, and had given informed consent to participate
in the study. To minimize selection bias, eligible patients
were enrolled consecutively during routine clinic visits.
Assessments
This study comprised of a two-part self-assessment
questionnaire (SAQ) including a retrospective cross-
sectional evaluation (SAQ1) and a prospective observa-
tional evaluation (SAQ2).
SAQ1 assessed baseline demographic and treatment in-
formation, hypoglycemia unawareness and perceptions of
hypoglycemia, history of severe hypoglycemia for 6 months
before the baseline visit, and “any” and “nocturnal”
hypoglycemia for 4 weeks before the baseline visit.
SAQ2 assessed severe and symptomatic hypoglycemia
and its effect on productivity and healthcare utilization
for 4 weeks from the baseline visit.
SAQ2 also included a validated diabetes-specific qual-
ity of life (DSQOL) questionnaire. To assist patients
Fig. 1 IO HAT Study design. Severe hypoglycemia: an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other
resuscitative actions; Non-severe hypoglycemia: documented symptomatic (symptoms and blood glucose measurement ≤3.9 mmol/L [70 mg/dL]) and
probable symptomatic (symptoms only). NSH= non-severe hypoglycemia; SH = severe hypoglycemia; SAQ= self-assessment questionnaire
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recall, and as a reminder to complete SAQ2, patients
were provided with a diary to capture hypoglycemic epi-
sodes. Paired responses to SAQ1 and SAQ2 were used
to estimate the differences in the frequency of
hypoglycemic episodes between the retrospective and
prospective periods. The incidence of severe and symp-
tomatic hypoglycemia (defined below) was calculated
according to the frequency of episodes over the timeframe
stated in the corresponding question. The diary which
allowed patients to summarize hypoglycemia information
on a daily basis over the 4-week period following the base-
line visit was used to evaluate the incidence of
hypoglycemia. If there were discrepancies between the
diary and the SAQ2 questionnaire, the frequency of
hypoglycemia was calculated using the highest recorded
total frequency as stated on either of these forms.
Hypoglycemia unawareness was evaluated through the
question: ‘Do you have symptoms when you have a low
sugar level?’ where the response, ‘occasionally’ denoted
impaired awareness and ‘never’ denoted severely im-
paired awareness [12]. Fear of hypoglycemia was re-
ported as rated by the patient on a scale of 0 (not afraid
at all) to 10 (absolutely terrified).
Study objectives
The primary objective of the study was to determine the
percentage of patients experiencing at least 1 hypoglycemic
episode during the 4-week prospective observational period
among insulin-treated T1DM or T2DM patients.
The secondary objectives included: incidence of
hypoglycemic episodes, difference in the incidence of
hypoglycemic episodes before and after the baseline visit,
relationship between patient demography, treatment,
and hypoglycemia, use of health-care resources, and
types of behaviors against hypoglycemia. Diabetes-
related late complications, treatment regimen and
glycemic control were ascertained from questions com-
pleted in the presence of the participant’s health-care
professional to improve accuracy.
All other study end-points including the primary end-
point of interest were determined from questions com-
pleted by the patient.
Hypoglycemia classification
Severe hypoglycemia was defined as: requiring third-party
assistance, based on the American Diabetes Association
(ADA) definition [13]; non-severe hypoglycemia: managed
by patient alone; any hypoglycemia: the sum of severe and
non-severe hypoglycemia; nocturnal hypoglycemia: event
occurring between midnight and 06:00 h.
Sample size
Sample size of the total cohort across 9 countries of the
IO HAT study was determined to be 6000 patients
assuming a worst case scenario proportion of patients
(50%) reporting at least 1 hypoglycemic episode during
the 4-week prospective observation period, and that the
range of the 95% confidence interval was < 3 percentage
point for the total cohort. Of these, 2000 patients were
planned to be recruited from Turkey.
Evaluability of patients for analysis
Patients who returned any part of any SAQ or patient
diary containing answers to any of the questions re-
ceived was also included in the Full Analysis Set (FAS).
Statistical methods
All statistical tests were two-sided and regarded as ex-
ploratory, with the criterion for statistical significance set
at p < 0.05. The p-values from 0.01 to 0.05 were taken to
indicate a modest evidence of a difference, and p-values of
< 0.01 were taken to indicate moderate evidence.
For the primary endpoint, the percentage of patients
who experienced at least 1 hypoglycemic episode during
the 4-week prospective observational period among
T1DM or T2DM patients was calculated together with
the confidence interval for this percentage. For second-
ary endpoints, the incidence of various types of
hypoglycemia was calculated as number of episodes per
patient-year (ppy) as expressed by the following formula
(together with the 95% confidence interval).
Incidence rate = Total number of events / Total
follow-up time (patient-years).
The incidence rate (IR) was reported by diabetes type:
T1DM and T2DM patients. No imputation of missing
data was performed except for calculation of Well-Being
Questionnaire-5 summary scores where more than half
the items were non-missing. All analyses were con-
ducted in the FAS.
Relationship between HbA1c at baseline and log-
transformed number of hypoglycemia events reported by
patients was shown by the scatter plot with regression
line and 95% confidence interval (CI) and R-squared
values were calculated.
Baseline refers to data collected using the Part 1 SAQ;
follow-up refers to data collected using the Part 2 SAQ
and, where applicable, patient diaries.
Results
Patient characteristics
Overall, 2348 patients (306 with T1DM and 2042 with
T2DM) from Turkey enrolled and completed the Part 1
SAQ in the Turkey cohort constituting the FAS. Of
these, 252 patients (82.4%) with T1DM and 1781 pa-
tients (87.2%) with T2DM completed the Part 2 SAQ;
and 247 patients (80.7%) with T1DM and 1749 patients
(85.7%) with T2DM completed the patient diary and
were included in the completers analysis set (CAS).
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Baseline characteristics for T1DM and T2DM patients
in the FAS are presented in Table 1. Patients with T1DM
were younger than those with T2DM (32.7 years vs.
58.0 years, respectively) and had a longer median
duration of insulin use (11.2 years vs. 6.0 years, respect-
ively). Mean HbA1c was lower in patients with T1DM
(8.4% [67.9 mmol/mol]) than in those with T2DM (8.8%
[72.3 mmol/mol]).
Frequency of hypoglycemia
Any hypoglycemia
Any hypoglycemia rates in T1DM and T2DM patients
are presented in Figs. 2 and 3, respectively. In T1DM
patients, 96.8% patients reported hypoglycemic events
(IR: 68.6 events ppy), prospectively, while 74.0% patients
reported hypoglycemic events (IR: 51.7 events ppy),
retrospectively. In T2DM patients, 95.9% patients (IR:
28.3 events ppy) reported hypoglycemic events, pro-
spectively, while 53.6% patients (IR: 23.0 events ppy)
reported hypoglycemic events, retrospectively.
The rates of any hypoglycemia were significantly
higher in the prospective period compared with the
retrospective period in both T1DM and T2DM patients
(T1DM, p = 0.005; T2DM, p < 0.001).
Nocturnal hypoglycemia
Nocturnal hypoglycemia rates in T1DM and T2DM
patients are presented in Figs. 2 and 3, respectively.
Unlike, any hypoglycemia, the retrospective rates for
nocturnal hypoglycemia were higher compared to the
prospective rates in both T1DM and T2DM patients;
40.9% vs. 35.0% (IR: 18.0 ppy vs. 12.4 ppy) in T1DM,
15.2% vs. 10.6% (IR:5.0 ppy vs. 2.6 ppy) in T2DM;
(T1DM, p = 0.017; T2DM, p < 0.001).
Severe hypoglycemia
Severe hypoglycemia rates in T1DM and T2DM patients
are presented in Figs. 2 and 3, respectively. In T1DM pa-
tients, in the 6-month retrospective period, severe
hypoglycemia was reported by 54.7% (IR: 8.9 events ppy)
patients, while in the 4-week prospective period, severe
hypoglycemia was reported by 53.3% (IR: 15.3 events ppy)
patients. In T2DM patients, 50.1% (IR: 4.1 events ppy)
and 61.9% (IR: 10.0 events ppy) patients reported severe
hypoglycemia, retrospectively and prospectively. The rates
of severe hypoglycemia were significantly higher in the
prospective period compared with those in the retrospect-
ive period (T1DM, p = 0.005; T2DM, p < 0.001).
Use of health system resources
The impact of hypoglycemia on the medical system was
higher in the 6-month retrospective period than in the
4-week prospective period for both T1DM and T2DM
patients (Table 2).
Hypoglycemia requiring hospitalization
In T1DM patients, 10.2% patients (6-month retrospective
period) and 3.3% patients (4-week prospective period) re-
ported hypoglycemia requiring hospitalization. In T2DM
patients, 6.1% patients (6-month retrospective period) and
1.9% patients (4-week prospective period) reported
hypoglycemia requiring hospitalization (Table 2).
Requiring additional clinic appointments
In T1DM patients, 15.8% (6-month retrospective period)
and 12.6% (4-week prospective period) patients required
additional clinic appointments. In T2DM patients, 11.4%
(6-month retrospective period) and 8.0% (4-week pro-
spective period) required additional clinic appointments
(Table 2).
Requiring number of additional telephone contacts made
In T1DM patients, 6.3% patients (6-month retrospective
period) and 5.3% patients (4-week prospective period)
made additional telephone contacts. In T2DM patients,
4.1% patients (6-month retrospective period) and 3.3%
patients (4-week prospective period) made additional
telephone contacts (Table 2).
Patient response to hypoglycemia
The overall patient actions resulting from hypoglycemia
were more in the 6-month retrospective period than in
the 4-week prospective period in both T1DM and T2DM
patients (Table 2). For patients with T1DM, the 6-month
retrospective and 4-week prospective data, respectively,
were: the percentage of patients who consulted their
doctor or nurse (47.4% vs. 32.9%), required any form of
medical assistance (48.7% vs. 33.3%), increased calorie in-
take (35.3% vs. 28.6%), avoided physical exercise (17.6% vs.
13.1%), reduced insulin dose (35.0% vs. 18.7%), skipped
insulin injections (23.9% vs. 10.3%), and increased blood
glucose monitoring (52.3% vs. 46.4%).
In the T2DM patients, the 6-month retrospective and
4-week prospective data, respectively, were: the percent-
age of patients who consulted their doctor or nurse
(39.3% vs. 32.6%), required any form of medical assist-
ance (41.0% vs. 32.6%), increased calorie intake (27.6%
vs. 17.6%), avoided physical exercise (11.3% vs. 9.2%),
reduced insulin dose (18.8% vs. 13.0%), skipped insulin
injections (18.0% vs. 9.8%), and increased blood glucose
monitoring (28.9% vs. 20.9%).
Impact of hypoglycemia on work/studies
Higher percentage of patients took leave from work/
studies, arrived late or left early from work/studies in
the retrospective period than the prospective period
(Table 2). In T1DM patients, the 6-month retrospective
and 4-week prospective data, respectively were: 22.0%
vs. 6.6% patients had taken leave from work/studies,
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24.5% vs. 9.0% patients had arrived late to work/studies,
and 20.5% vs. 11.4% patients left early from work/stud-
ies. In T2DM patients, the 6-month retrospective and
4-week prospective data, respectively were: 10.8% vs.
3.1% patients had taken leave from work/studies, 6.4%
vs. 2.5% patients had arrived late to work/studies, and
10.8% vs. 2.5% patients left early from work/studies.
Hypoglycemia awareness
More patients with T1DM than with T2DM had know-
ledge of hypoglycemia before reading the definition in the
Part 1 SAQ (91.3% [T1DM] and 60.4% [T2DM]) and had
a higher normal hypoglycemia awareness (71.6% [T1DM]
and 53.3% [T2DM]) (Table 2). There were no notable dif-
ferences between patients with T1DM or T2DM with re-
spect to fear of hypoglycemia, with a mean (standard
deviation) score of 5.3 (3.6) for patients with T1DM and
4.5 (3.6) for patients with T2DM (Table 2).
Hypoglycemia by insulin regimen
Incidence rates of any hypoglycemia in T1DM and
T2DM patients in the 4-week retrospective and
prospective assessment periods by insulin regimen
(short-acting, long-acting, pre-mix, and short- plus long-
acting) are shown in Figs. 4 and 5, respectively.
Estimated IRs of any and severe hypoglycemia increased
whilst estimated IRs of nocturnal hypoglycemia generally
decreased in the prospective period versus the retro-
spective period in patients with T1DM and T2DM.
The estimated IRs of any hypoglycemic events in the
4-week retrospective and 4-week prospective assessment
were highest in patients with T1DM using short-acting
insulin in the prospective period (86.2 ppy) and lowest
in patients with T2DM using long-acting insulin, in the
retrospective period (11.9 ppy).
The IRs of nocturnal hypoglycemia were highest in pa-
tients with T1DM using short-acting insulin in the
4-week retrospective period (20.5 events ppy) and lowest
Table 1 Baseline characteristics
T1DM
(N = 306)
T2DM
(N = 2042)
Age (years) 32.7 (11.6) 58.0 (10.5)
Median 30.5 58.0
Upper quartile, Lower quartile 39.0, 24.0 65.0, 51.0
Male/female (%) 44.1/55.9 40.9/59.1
Duration of diabetes (years) 12.1 (8.0) 12.5 (7.0)
Median 10.5 11.0
Upper quartile, lower quartile 17.0, 6.0 17.0, 7.0
Duration of insulin use (years) 11.2 (7.8) 6.0 (4.6)
Median 10.0 5.0
Upper quartile, lower quartile 16.0, 5.0 8.0, 3.0
HbA1c (mmol/mol) 67.9 (18.1) 72.3 (20.4)
HbA1c (%) 8.4 (1.7) 8.8 (1.9)
FBG (mmol/L) 8.6 (4.1) 9.6 (4.0)
FBG (mg/dL) 155.0 173.0
PPG (mmol/L) 11.1 (4.8) 12.5 (4.9)
PPG (mg/dL) 200.0 (86.5) 225.2 (88.3)
Weight (kg) 70.4 (16.2) 83.7 (14.9)
Median 68.0 82.0
Upper quartile, lower quartile 80.0, 60.0 92.0, 74.0
Height (cm) 167.8 (10.0) 164.2 (8.5)
Median 168.0 164.0
Upper quartile, lower quartile 174.0, 160.0 170.0, 158.0
BMI (kg/m2) 25.0 (5.2) 31.2 (5.7)
Median 24.3 30.5
Upper quartile, lower quartile 27.2, 21.8 34.0, 27.3
Previous medical illnesses % of patients % of patients
Neuropathy 34.6 53.1
Retinopathy 20.6 39.6
Nephropathy 9.2 14.6
Peripheral vascular disease 14.7 20.2
Angina 9.8 17.4
Myocardial infarction 3.3 15.6
None 49.0 27.7
Symptoms of diabetes-related complications, %
Any 98.4 95.4
Tremor 84.0 80.5
Sweating 85.6 79.4
Hunger 83.0 78.2
Tiredness 83.0 76.4
Weakness 78.4 72.9
Diabetes treatment regimen, %
Short-acting insulin 12.1 5.5
Long-acting insulin 4.6 17.3
Table 1 Baseline characteristics (Continued)
T1DM
(N = 306)
T2DM
(N = 2042)
Pre-mix 4.2 33.3
Both short- and long-acting 74.2 41.1
Both short-acting and pre-mix 0.3 0.6
Both long-acting and pre-mix 3.3 1.4
Short- and long-acting and pre-mix 0.0 0.0
Missing 1.3 0.8
Data are presented as mean (SD) unless otherwise stated
BMI = body mass index, FBG = fasting blood glucose, HbA1c = glycated
hemoglobin, N = total number of patients participating, PPG = postprandial
glucose, SD = standard deviation, T1DM = type I diabetes mellitus, T2DM = type
II diabetes mellitus
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in the 4-week prospective period in T2DM patients
using short-acting insulin (1.1 events ppy).
The IRs of severe hypoglycemia were highest in
T1DM patients using pre-mix insulin in the 4-week pro-
spective period (19.6 ppy) and lowest in T1DM patients
using long-acting insulin in the 6-month retrospective
period (1.2 ppy).
Associations between hypoglycemia and continuous or
predictor variables
In this study, no correlation was observed between baseline
HbA1c and any hypoglycemia events in both T1DM and
T2DM populations (Figs. 6 and 7, respectively). No signifi-
cant association between hypoglycemia and duration of
diabetes or duration of insulin therapy was seen
(Additional files 1 and 2, respectively). Patients who mea-
sured their blood glucose levels more frequently reported
higher rates of hypoglycemia compared to those who moni-
tored their blood glucose levels less frequently (Fig. 8).
Discussion
This paper describes the results from the Turkey cohort
of the international, non-interventional, multicenter,
retrospective and prospective study to assess the inci-
dence of patient-reported hypoglycemia in insulin-
treated diabetes patients.
This is a first report of an observational study to assess
hypoglycemia both retrospectively and prospectively in
the Turkish T1DM and T2DM patients. While
hypoglycemia has been reported from a few observa-
tional studies in Turkish population, the main aim of
these studies were not to assess hypoglycemia. Minor
hypoglycemia rates of 1.08 and 2.56 ppy were prospect-
ively observed in the insulin detemir and insulin glargine
group, respectively, in the Turkish T2DM cohort from
the observational SOLVE study [10]. The lower
hypoglycemic frequencies obtained in these studies
could be explained by the fact that hypoglycemia assess-
ment was not the primary objective of these studies and
Fig. 3 Estimated rate of retrospective and prospective hypoglycemia in T2DM (any, nocturnal, and severe hypoglycemia). ‘Any’ and ‘Nocturnal’
based on 4-week period for both retrospective and prospective analyses. *Retrospective data based on 6-month period and prospective data
based on 4-week period. RR = rate ratio; T2DM = type II diabetes mellitus
Fig. 2 Estimated rate of retrospective and prospective hypoglycemia in T1DM (any, nocturnal, and severe hypoglycemia). ‘Any’ and ‘Nocturnal’
based on 4-week period for both retrospective and prospective analyses. *Retrospective data based on 6-month period and prospective data
based on 4-week period. RR = rate ratio; T1DM = type I diabetes mellitus
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Table 2 Patient perspectives on hypoglycemia
T1DM T2DM
Impact of hypoglycemic events on the medical system (%) Retrospective
(n = 306)
Prospective
(n = 253)
Retrospective
(n = 2042)
Prospective
(n = 1796)
Events requiring hospital admission 10.2 3.3 6.1 1.9
Attended additional clinical appointments 15.8 12.6 11.4 8.0
Made additional telephone contacts 6.3 5.3 4.1 3.3
Patient response to hypoglycemia (%) Retrospective
(n = 306)
Prospective
(n = 252)
Retrospective
(n = 2042)
Prospective
(n = 1781)
Consulted their doctor/nurse 47.4 32.9 39.3 32.6
Required any form of medical assistance 48.7 33.3 41.0 32.6
Increased calorie intake 35.3 28.6 27.6 17.6
Avoided physical exercise 17.6 13.1 11.3 9.2
Reduced insulin dose 35.0 18.7 18.8 13.0
Skipped insulin injections 23.9 10.3 18.0 9.8
Increased blood glucose monitoring 52.3 46.4 28.9 20.9
Impact of hypoglycemic events on work and study (%) Retrospective
(n = 200)
Prospective
(n = 166)
Retrospective
(n = 360)
Prospective
(n = 321)
Taken leave from work or studies 22.0 6.6 10.8 3.1
Arrived late to work/studies 24.5 9 6.4 2.5
Left early from work/studies 20.5 11.4 10.8 2.5
T1DM (N = 306) T2DM (N = 2042)
Knew what hypoglycemia was at baseline before Part 1 SAQ (%)
91.3 60.4
Defined hypoglycemia based on (%)
Symptoms only 54.6 52.4
Blood glucose measurement only 2.3 3.5
Either 15.4 15.2
Both 24.2 18.8
Hypoglycemia awareness (%)
Normal 71.6 53.3
Impaired 25.2 38.5
Severely impaired 0.7 2.8
Fear of hypoglycemia (Scale of 0 to 10; %)
0 = no fear 19.9 24.3
1 3.9 5.9
2 2.3 5.8
3 5.6 5.4
4 5.6 4.6
5 13.1 10.7
6 6.5 6.6
7 9.8 9.9
8 10.1 8.7
9 5.2 4.6
10 = absolutely terrified 17.3 12.2
Hypoglycemia unawareness was evaluated through the question: ‘Do you have symptoms when you have a low sugar level?’ where the response, ‘occasionally’
denoted impaired awareness and ‘never’ denoted severely impaired awareness
N = total number of patients participating; n = number of patients who responded to the set of questions; SAQ = self-assessment questionnaire; T1DM= type
I diabetes mellitus; T2DM= type II diabetes mellitus
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the reported frequency is for minor hypoglycemia which
may not encompass a total hypoglycemic rate. Total
hypoglycemic episodes in the 4-week retrospective
period in the PREDICTIVE study were 47.5 ppy in pa-
tients with T1DM and 9.2 ppy in patients with T2DM in
the European cohort (Turkey population was included)
[14], which are comparable to those for T1DM popula-
tion but less compared to T2DM population observed in
the current study (51.7 ppy and 23.0 ppy, respectively).
The hypoglycemia rates seen in the IO HAT Turkey co-
hort aligned with the overall IO HAT results [15]. The fre-
quency of overall hypoglycemia in the prospective period
in the Turkey cohort was comparable to global HAT in
T1DM patients but was considerably higher in T2DM pa-
tients (28.3 events ppy) than the global HAT study (19.3
events ppy). The reason for this could be the country-
specific variations in the prevalence and management of
diabetes and hypoglycemia in the two studies.
Similar to the overall IO HAT results, higher frequency
of patients reported hypoglycemia in the prospective
period as compared to the retrospective period in both
T1DM and T2DM patients in the Turkey cohort. The rea-
son for this could be the use of patient diary during the
prospective period. While a patient recorded data daily
using patient diary during the prospective period, the data
for the retrospective period was collected at baseline visit
based on the patient’s memory of the previous
hypoglycemic events, possibly causing under-reporting.
The patient education on hypoglycemia at the baseline
visit could have also led to an improved reporting of
Fig. 4 Estimated rate of any hypoglycemic event by insulin regimen in T1DM. Data based on 4-week period for both retrospective and prospective
analyses. S + L = short-acting and long-acting insulin; T1DM= type I diabetes mellitus; n = number of patients
Fig. 5 Estimated rate of any hypoglycemic event by insulin regimen in T2DM. Data based on 4-week period for both retrospective and prospective
analyses. S + L = short-acting and long-acting insulin; T2DM= type 2 diabetes mellitus; n = number of patients
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hypoglycemia in the prospective period. On similar lines,
the higher frequency of severe hypoglycemia observed
during the prospective period over the retrospective
period in both T1DM and T2DM patients could also be
explained. However, a lower frequency of nocturnal
hypoglycemia was reported in the prospective period over
the retrospective period. This could be because of a well-
defined cut-off for the nocturnal hypoglycemia, midnight
to 06.00 am, during the prospective period. The perceived
fear of nocturnal hypoglycemia could also probably cause
an over-reporting of events during the retrospective
period based on patient recall. Also, difficulty in using a
diary during the night-time could have affected the report-
ing of nocturnal hypoglycemia during the prospective
period. Interestingly, though the prospectively reported
“any” and “severe” hypoglycemia rates were higher than
retrospectively reported rates, a higher proportion of pa-
tients reported increased utilization of healthcare re-
sources (hospital admissions, additional clinical
appointments) in the retrospective period than the
prospective period. Similarly, a higher proportion of pa-
tients reported that the hypoglycemic events impacted
their work and study in the retrospective period than in
the prospective period. The reason for this could be be-
cause the patients were well-informed about hypoglycemia
at the baseline visit leading to less impact on patients’
quality of life in the prospective period. Another explan-
ation could be that the assessment period for some of the
parameters in the retrospective period was of 6 months
compared to 4 weeks during the prospective period and
hence the difference.
In the PREDICTIVE study, the frequency of
hypoglycemia in insulin-treated patients showed a signifi-
cant, positive association with duration of diabetes, and
number of insulin injections but was inversely related to
HbA1c [14]. Unlike the global HAT study [11], no signifi-
cant correlation of hypoglycemia with duration of diabetes
and insulin therapy was seen in the current study. Also,
no significant correlation between HbA1c and
hypoglycemia was observed which is in line with global
a b
Fig. 6 Relationship between HbA1c and number of events – any hypoglycemic event in T1DM. a Proportion of patients experiencing any hypoglycemia
during the retrospective and prospective periods, stratified by HbA1c levels at baseline b Scatter plot with regression line and 95% confidence interval for
relationship between HbA1c at baseline and log-transformed number of events for patients experiencing any hypoglycemia before or after baseline.
HbA1c = hemoglobin A1c; T1DM= type I diabetes mellitus
a b
Fig. 7 Relationship between HbA1c and number of events – any hypoglycemic event in T2DM. a Proportion of patients experiencing any hypoglycemia
during the retrospective and prospective periods, stratified by HbA1c levels at baseline b Scatter plot with regression line and 95% confidence interval for
relationship between HbA1c at baseline and log-transformed number of events for patients experiencing any hypoglycemia before or after baseline.
HbA1c = hemoglobin A1c; T2DM= type I diabetes mellitus
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HAT study results [11] and recent findings that the in-
verse correlation between HbA1c and hypoglycemia has
diminished due to advances in therapy in the recent years
[16]. A regular self-monitoring of blood glucose is import-
ant to detect hypoglycemia and for overall diabetes man-
agement [17]. A positive correlation between frequency of
blood glucose monitoring and reported hypoglycemia
rates was seen in the current study which suggests its im-
portance to detect hypoglycemia.
Conclusions
The current study has enabled to obtain real-world data on
hypoglycemia rates from Turkey where very few data were
available in spite of a high rate of diabetes prevalence. The
results from this study confirms that hypoglycemia remains
under-reported. The higher hypoglycemic rates observed
in Turkish population could be because of higher burden
of diabetes combined with lack of standard care and treat-
ment as compared to European and North American
population and needs to be investigated further. The
hypoglycemia data in Turkish cohort is an important step
towards a customized country-specific healthcare plan to
control diabetes.
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